Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Regeneron Pharmaceuticals, Inc. (REGN) had Debt to Equity Ratio of 0.10 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$13.12B |
|
$3.95B |
|
$1.82B |
|
$11.30B |
|
$9.07B |
|
$4.05B |
|
$152.20M |
|
$4.20B |
|
$4.20B |
|
$3.95B |
|
$3.95B |
|
$3.95B |
|
$3.95B |
|
$4.05B |
|
$4.47B |
|
106.70M |
|
113.70M |
|
$37.05 |
|
$34.77 |
|
| Balance Sheet Financials | |
$19.48B |
|
$4.15B |
|
$13.60B |
|
$33.08B |
|
$3.42B |
|
$2.70B |
|
$3.68B |
|
$7.11B |
|
$25.97B |
|
$24.93B |
|
$25.97B |
|
109.40M |
|
| Cash Flow Statement Financials | |
$4.59B |
|
$-3.19B |
|
$-1.79B |
|
$3.12B |
|
$2.74B |
|
$-381.60M |
|
$885.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.69 |
|
-- |
|
-- |
|
0.09 |
|
|
Debt to Equity Ratio |
0.10 |
86.16% |
|
30.85% |
|
30.85% |
|
34.06% |
|
32.01% |
|
30.14% |
|
$3.88B |
|
-- |
|
-- |
|
-- |
|
0.40 |
|
0.70 |
|
2.31 |
|
157.70 |
|
15.22% |
|
15.86% |
|
11.95% |
|
13.79% |
|
$237.41 |
|
$34.08 |
|
$40.40 |
|